The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
No injuries after debris incident in central Dubai
UAE air forces respond to more missile threats on Friday
Abu Dhabi expands driverless taxi operations in Yas Island
UAE air defences intercept 10 ballistic missiles and 26 drones on Thursday
UAE allows residents with expired residency visas to re-enter
Sharjah issues public safety guide for emergencies
UAE and Syrian Presidents stress importance of dialogue, diplomacy
Dubai Health reports 46% rise in kidney transplants
